Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Dosimetry of 177Lu-EB-PSMA-617 in mCRPC
NCT03403595Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-EB-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Standardized Uptake Value at 168 hours. Status: unknown.
02
Drugs
177Lu-EB-PSMA-617
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03403595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03403595.